TFRC and myeloid sarcoma: Moreover, although MS patients have significantly reduced circulating TFR cells compared to healthy controls (HC), residual circulating TFR cells with a TH17 effector phenotype and impaired suppressive activity are increased in MS patients [14], while TH17 cells are essential to MS pathogenesis [15, 16].